GOFINTECH QUANT's stock price surged 5.10% during intraday trading on Monday, reflecting significant investor interest in the company's latest strategic development.
The sharp rise follows the company's announcement of a strategic cooperation memorandum of understanding (MOU) with MedGraph Bio (Suzhou) Life Science Technology Co., Ltd. The partnership involves a milestone-based licensing model across three key areas: asset licensing and acquisition of MedGraph Bio's quantum computing drug discovery systems (including QureGen AI and TyxonQ platforms), co-launching a quantum frontier technology investment fund targeting biopharmaceuticals and advanced materials, and jointly establishing a quantum computing center in Hong Kong focused on application R&D.
The board believes this collaboration will enhance the company's technological competitiveness in the quantum-AI convergence era and diversify its potential revenue streams, marking a strategic expansion into quantum AI-driven drug discovery.